Lobular carcinoma in situ (LCIS) of the left breast is a non-invasive breast cancer characterized by abnormal cell growth in the lobules of the breast. While LCIS is not considered a true breast cancer, it is a marker for increased risk of developing invasive breast cancer in the future. Accurate coding with ICD-10 Code D05.02 is essential for proper diagnosis, documentation, medical billing, and public health reporting, ensuring that patients receive appropriate surveillance and management.
ICD-10 Code D05.02 specifically denotes lobular carcinoma in situ of the left breast. This condition involves the proliferation of atypical cells within the lobules, which can lead to an increased risk of subsequent invasive breast cancer. This code should be utilized in clinical documentation and billing when diagnosing patients with LCIS, ensuring accurate representation of the patient's condition for treatment planning and insurance reimbursement.
Lobular carcinoma in situ of the left breast is a non-invasive neoplasm that arises from the lobular epithelium. It is characterized by small, non-cohesive clusters of atypical cells that fill the lobules. Although it does not typically present with symptoms, it requires careful monitoring due to its association with an elevated risk of developing invasive breast cancer.
In SOAP notes, ICD-10 Code D05.02 is utilized to document the diagnosis of lobular carcinoma in situ of the left breast. This code plays a crucial role in capturing the patient's clinical history, assessment findings, and treatment plans, facilitating continuity of care and appropriate billing in both acute and chronic care settings.
ICD-10 Code D05.02 connects subjective patient reports and objective clinical findings to a formal diagnosis of lobular carcinoma in situ of the left breast. This code is essential for ensuring continuity of care, supporting accurate billing, and meeting electronic health record documentation standards.
Management of lobular carcinoma in situ of the left breast typically involves careful monitoring rather than immediate invasive treatment. Regular follow-up is essential to assess for any progression to invasive disease.


HIPAA-compliant and designed with privacy in mind, your patient’s data is protected. Focus on care while we safeguard your information.
Learn moreICD-10 Code D05.02 is critical in medical billing, particularly in hospital and outpatient settings, to ensure accurate reimbursement for services related to lobular carcinoma in situ of the left breast.
| CPT Code | Description |
|---|---|
| 99213 | Established patient office visit, Level 3. |
| 77067 | Mammography, bilateral, including CAD. |
| 88305 | Level IV surgical pathology, gross and microscopic examination. |
Common Questions About Using ICD-10 Code D05.02 for Lobular carcinoma in situ of left breast
What is lobular carcinoma in situ?
Lobular carcinoma in situ (LCIS) is a non-invasive condition where abnormal cells grow in the lobules of the breast. While it is not considered breast cancer, it indicates an increased risk for developing invasive breast cancer in the future.
How is lobular carcinoma in situ diagnosed?
LCIS is typically diagnosed through a breast biopsy, often performed after an abnormal mammogram or clinical examination. It may be discovered incidentally during the evaluation of other breast conditions.
What are the treatment options for lobular carcinoma in situ?
Management of LCIS usually involves regular monitoring and surveillance rather than immediate treatment. Patients may be advised on lifestyle changes and risk-reducing strategies.
Is lobular carcinoma in situ hereditary?
While LCIS itself is not hereditary, it is associated with genetic factors that may increase breast cancer risk. Family history should be evaluated to determine the need for genetic counseling.
Clinical Notes
SOAP notes
DAP notes
AI medical notes